Viemed Healthcare (VMD) EBITDA (2018 - 2026)

Viemed Healthcare (VMD) has reported EBITDA for 9 consecutive years, with $4.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 12.44% year-over-year to $4.5 million; the trailing twelve-month figure through Jun 2026 stood at $22.8 million (up 8.35% YoY), and the FY2025 full-year result was $22.9 million, up 28.21% from the prior year.
• EBITDA grew to $4.5 million in Q2 2026 per VMD's latest filing, from $4.3 million in the prior quarter.
• Across five years, EBITDA topped out at $10.2 million in Q3 2023 and bottomed at $2.2 million in Q1 2024.
• Historically, EBITDA has averaged $5.8 million across 5 years, with a median of $5.6 million in 2022.
• The sharpest annual moves came in 2023 and 2024: EBITDA jumped 82.13% in 2023, then plunged 67.08% in 2024.
• Over 5 years, EBITDA stood at $7.9 million in 2022, then sank by 33.11% to $5.3 million in 2023, then rose by 21.99% to $6.5 million in 2024, then advanced by 29.74% to $8.4 million in 2025, then plunged by 46.71% to $4.5 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $4.5 million, $4.3 million, and $8.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.